AFT PharmaceuticalsNZSE:AFT +0.54%96 Days Payable is 66.24 as of Mar. 2026, which is 2% below its 10-year median of 67.70. GuruFocus rates NZSE:AFT with a GF Score™ of 96/100 and a GF Value™ of NZ$4.15 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 920 Drug Manufacturers companies, AFT Pharmaceuticals ranks worse than 62.39% on this metric.
The historical rank and industry rank for AFT Pharmaceuticals's Days Payable or its related term are showing as below:
NZSE:AFT'
s Days Payable Range Over the Past 10 Years
Min: 48.69 Med: 67.7 Max: 80.93
Current: 69.54
During the past 11 years, AFT Pharmaceuticals's highest Days Payable was 80.93. The lowest was 48.69. And the median was 67.70.
NZSE:AFT's Days Payable is ranked worse than 62.39% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs NZSE:AFT: 69.54
AFT Pharmaceuticals's Days Payable
declined
from Mar. 2025 (69.89) to Mar. 2026 (66.24).
It may suggest that AFT Pharmaceuticalsaccelerated paying its suppliers.
AFT Pharmaceuticals Days Payable Related Terms
AFT Pharmaceuticals Days Payable Historical Data
* Premium members only.
The historical data trend for AFT Pharmaceuticals's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:AFT vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
AFT Pharmaceuticals's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AFT Pharmaceuticals (NZSE:AFT) has a Days Payable of 66.24 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on AFT Pharmaceuticals and its competitors. This is near median its historical median of 67.70. Over the past decade, AFT Pharmaceuticals' Days Payable has ranged from 48.69 to 80.93. According to the industry distribution chart, AFT Pharmaceuticals ranks #574 out of 920 companies in the Drug Manufacturers industry, placing it in the top 62.4%.
Is AFT Pharmaceuticals' Days Payable too high?
AFT Pharmaceuticals' current Days Payable of 66.24 is near median its 10-year median of 67.70. Over the past 10 years, this metric has ranged from a low of 48.69 to a high of 80.93. The Drug Manufacturers industry median Days Payable is 90.84. AFT Pharmaceuticals' value of 66.24 is 27.1% below this industry median. Based on the distribution chart, AFT Pharmaceuticals ranks #574 out of 920 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, AFT Pharmaceuticals has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #574 out of 920 companies for Days Payable. This places AFT Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 90.84. AFT Pharmaceuticals' value of 66.24 is 27.1% below this benchmark. Historically, AFT Pharmaceuticals' own Days Payable has ranged from 48.69 to 80.93 over the past decade. While the company's 10-year median is 67.70 vs. the industry median of 90.84, AFT Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AFT Pharmaceuticals's current Days Payable of 66.24 is 27.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on AFT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current Days Payable is 66.24, which is near median its own 10-year median of 67.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (NZSE:AFT) is currently considered Modestly Undervalued. The stock's GF Value™ is NZ$4.15, compared to a current price of NZ$3.70 — trading 10.8% below its estimated fair value. The current Days Payable is 66.24, which is near median its 10-year median of 67.70 and 27.1% below the Drug Manufacturers industry median of 90.84. AFT Pharmaceuticals' overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For AFT Pharmaceuticals (NZSE:AFT), the current Days Payable is 66.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (NZSE:AFT) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued.
The current stock price of NZ$3.70 is trading 10.8% below its estimated GF Value™ of NZ$4.15.
GuruFocus considers AFT Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NZSE:AFT:
Days Payable: 66.24 (near median its 10-year median of 67.70)
GF Value™: NZ$4.15 vs. price of NZ$3.70 (10.8% below fair value)
Industry Position: 27.1% below the Drug Manufacturers median (#574 of 920)
No single metric tells the full story. See the NZSE:AFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
96GF Score
Get the complete analysis for NZSE:AFT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:AFT has been successfully added to your 
